Top Markets
#1 ADO Protocol ADO Protocol +329.47%
#2 GoPlus Security GoPlus Security +54.27%
#3 Nockchain Nockchain +46.24%
#4 Tutorial Tutorial +35.05%
#5 Starpower Starpower +34.11%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +31.96%
#7 The Black Bull The Black Bull +31.29%
#8 GAIB AID GAIB AID +24.67%
#9 Casper Network Casper Network +21.33%
#10 Verus Coin Verus Coin +20.40%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
China Regenerative Medicine International Limited China Regenerative Medicine International Limited

China Regenerative Medicine International Limited

8158
Rank in Stocks #32812
China Regenerative Medicine International Limited operates as an investment... China Regenerative Medicine International Limited operates as an investment holding entity, focusing on the development and distribution of a diverse portfolio of healthcare products and associated services. The company provides extensive health management solutions, covering health condition assessments, detoxification programs, fostering internal bodily balance, nourishing vital organs, and enhancing the immune system. Additionally, its beauty offerings encompass non-surgical medical aesthetics, essential dermatological care, anti-aging skin remedies, hair revitalization, skin firming treatments, localized body contouring, and intimate restoration services. Established in 1995, the organization was previously known as China Bio-Med Regeneration Technology Limited until its rebranding to China Regenerative Medicine International Limited in March 2015. Its headquarters are situated in Tsim Sha Tsui, Hong Kong.
Share Price
$0.02967889
Last synced: 2026-08-12
Market Cap
$9.03M
Change (1 day)
0.00%
Change (1 year)
-72.68%
Country
HK
Trade China Regenerative Medicine International Limited (8158)

Category

Healthcare
P/B ratio for China Regenerative Medicine International Limited (8158)
P/B ratio as of 2026 TTM: 0
According to China Regenerative Medicine International Limited latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for China Regenerative Medicine International Limited from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE